Browse by author
Lookup NU author(s): Simon Cotterill, Professor Louise Parker, Emeritus Professor Alan Craft
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background. The N7 protocol for poor-risk neuroblastoma uses dose-intensive chemotherapy (as in N6 protocol [Kushner et al.:] Clin Oncol 12:2607-2613, 1994] but with lower dosing of vincristine) for induction, surgical resection and 2100 cGy hyperfractionated radiotherapy for local control, and for consolidation, targeted radioimmunotherapy with 131I-labeled anti-GD2 3F8 monoclonal antibody and immunotherapy with unlabeled/unmodified 3F8 (400 mg/m2). Procedure. The chemotherapy consists of: cyclophosphamide 70 mg/kg/d × 2 and a 72-hr infusion of doxorubicin 75 mg/m2 plus vincristine 2 mg/m2, for courses 1, 2, 4, and 6; and cisplatin 50 mg/m2/d × 4 and etoposide 200 mg/m2/d × 3, for courses 3, 5, and 7. 131I-3F8 is dosed at 20 mCi/kg, which is myeloablative and therefore necessitates stem-cell support. Results. Of the first 24 consecutive previously untreated patients more than 1 year old at diagnosis, 22 were stage 4 and two were unresectable stage 3 with MYCN amplification. Chemotherapy achieved CR/VGPR in 21 of 24 patients. Twenty patients to date have completed treatment with 131I-3F8, and 15 patients have completed all treatment. With a median follow-up of 19 months, 18 of 24 patients remain progression-free. Conclusions. Major toxicities were grade 4 myelosuppression and mucositis during chemotherapy, and self-limited pain and urticaria during antibody treatment. Late effects include hearing deficits and hypothyroidism. © 2001 Wiley-Liss, Inc.
Author(s): Cotterill, S. J., Parker, L., More, L., Craft, A. W.
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: 8th Advances in Neuroblastoma Research Conference (1998)
Year of Conference: 2001
Pages: 227-230
Publisher: Medical and Pediatric Oncology: John Wiley & Sons, Inc.
DOI: 10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U
PubMed id: 11464891
